Key points are not available for this paper at this time.
Abstract: The advent of a new treatment strategy in the form of disease-modifying therapy for Alzheimer’s disease (AD) has been finally achieved after a prolonged wait. Lecanemab is one of such drugs that target the pathophysiology of the disease by lowering the amyloid-β plaques to change the course of this debilitating disease and to decline its further progress. It is a humanized IgG1 monoclonal antibody that was approved by the Food and Drug Administration in July 2023 for the treatment of patients with early AD and in patients with mild cognitive impairment or mild dementia.
Bhanwra et al. (Wed,) studied this question.